Overview
MOTS-c is a 16-amino-acid peptide encoded within mitochondrial DNA, acting as a signaling molecule that influences metabolic homeostasis.
- Endogenously expressed from mitochondrial DNA
- Synthesized for research use
- Subcutaneous injection
Mechanism of action
Activates AMPK and modulates folate-methionine cycles, improving glucose uptake, fatty-acid oxidation, and stress resistance in muscle and other tissues.
- · AMPK activation
- · Folate cycle modulation
- · Insulin signaling
- · AMPK
How it acts on the body
MOTS-c is one of the first 'mitokines' — peptides encoded inside the mitochondrial genome that act on the rest of the body. It is unusual because most hormones travel from organs to mitochondria; MOTS-c travels the other way. Under metabolic stress, mitochondria translate and release it, signaling whole-body adaptations like increased glucose uptake and fat oxidation.
Mechanistically it activates AMPK — the cellular energy sensor that is also the target of metformin and of exercise itself — but it does so via the folate-methionine pathway, which makes it a metabolic 'context' signal as much as a true hormone. Skeletal muscle is its main target tissue, and it appears to amplify the benefits of exercise rather than replace them.
Hormonal & endocrine impact
How this peptide is reported to shift specific hormones and signaling molecules. Directionality reflects research literature and preclinical models, not clinical prescribing data.
Curves are schematic shapes (sigmoid for increases/decreases, damped oscillation for modulation/stabilization) anchored to a 100% baseline. They communicate direction and tempo of change reported in research literature — not absolute hormone concentrations.
Effects on the body
Organ system effects
Improves glucose uptake and fatty-acid oxidation in skeletal muscle.
May reduce hepatic lipid accumulation in animal studies.
Modulates whole-body metabolic homeostasis without acting on classical endocrine glands.
Reported effects
Drawn from preclinical research, anecdote, and small-scale clinical observation. No evidence grades are assigned — most peptides on this page lack rigorous human trials.
- Anecdotal improvements in stamina and metabolic flexibility
- Preclinical reductions in age-related insulin resistance
- May complement training adaptations
Potential side effects
- · Injection-site reaction
- · Mild fatigue
- · Headache
- · Lightheadedness
- · Long-term human safety is not established
Drug interactions
Pairing context
- Regular resistance and aerobic trainingSynergistic with mitochondrial adaptation.
- Hypoglycemia-prone individualsMonitor glucose closely.